NIKKEI 225
38,385.73 +29.67 (+0.08%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.87 +0.85 (+1.09%) GOLD FUTURES
2,392.50 +32.60 (+1.38%) DOW
39,908.00 +349.89 (+0.88%) Bitcoin GBP
51,897.91 +3,334.98 (+6.87%)
Roche Holding AG (0QOK.IL)
| Previous close | 224.30 |
| Open | 226.10 |
| Bid | 220.20 x N/A |
| Ask | 231.40 x N/A |
| Day's range | 222.50 - 228.00 |
| 52-week range | 212.30 - 298.40 |
| Volume | |
| Avg. volume | 917,021 |
| Market cap | 191.607B |
| Beta (5Y monthly) | 0.18 |
| PE ratio (TTM) | 17.37 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 9.50 (3.99%) |
| Ex-dividend date | 16 Mar 2023 |
| 1y target est | N/A |
- GlobeNewswire
Roche announces FDA approval of one of the first HPV self-collection solutions in the U.S., expanding access and screening options to help eliminate cervical cancer
More than half of all U.S. cervical cancer patients are underscreened1, which makes reducing barriers to sample collection and increasing access to screenings crucial to ultimately helping eliminate this deadly disease.Each year in the U.S., more than 13,000 patients are diagnosed with cervical cancer and approximately 4,000 die from this preventable disease, caused by HPV infection.1Roche’s human papillomavirus (HPV) self-collection solution will improve access to testing by providing women the
- GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales declineDue to the appreciation of the Swiss franc against most currencies, sales were 6% lower when reported in CHFPharmaceuticals Division base business2 grew by 7%, driven by strong sales of medicines to treat severe diseases, su
- Globe Newswire
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2The National Comprehensive Cancer Network® (NCCN®) Guidelines recommend routine testing for ALK, EGF
